bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting Read more about bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting
bluebird bio Appoints Denice Torres to Board of Directors Read more about bluebird bio Appoints Denice Torres to Board of Directors
bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress Read more about bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress
Canaccord Genuity 40th Annual Growth Conference Read more about Canaccord Genuity 40th Annual Growth Conference
bluebird bio Announces August Investor Event Read more about bluebird bio Announces August Investor Event
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma Read more about Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma
New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1/2 Clinical Study of bluebird bio’s LentiGlobin™ Gene Therapy for Sickle Cell Disease at 25th EHA Congress Read more about New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1/2 Clinical Study of bluebird bio’s LentiGlobin™ Gene Therapy for Sickle Cell Disease at 25th EHA Congress
Majority of Evaluable Patients Across Genotypes Achieve Transfusion Independence and Maintain It with Near-Normal Hemoglobin Levels in Phase 3 Studies of betibeglogene autotemcel (LentiGlobin™ for β-thalassemia) Gene Therapy Presented at EHA Congress Read more about Majority of Evaluable Patients Across Genotypes Achieve Transfusion Independence and Maintain It with Near-Normal Hemoglobin Levels in Phase 3 Studies of betibeglogene autotemcel (LentiGlobin™ for β-thalassemia) Gene Therapy Presented at EHA Congress
bluebird bio Announces That Its 2020 Annual Meeting of Stockholders Will Be Held in Virtual Format Read more about bluebird bio Announces That Its 2020 Annual Meeting of Stockholders Will Be Held in Virtual Format
Goldman Sachs 41st Annual Global Healthcare Conference Read more about Goldman Sachs 41st Annual Global Healthcare Conference